Table 2.
Trial characteristics of completed and terminated GBM-related clinical trials
| Completed trials | Terminated trials | Total | p value | |
|---|---|---|---|---|
| n = 711 (80.2%) | n = 175 (19.8%) | n = 886 (100%) | ||
| Primary treatment | ||||
| Behavioral | 4 (100%) | 0 (0%) | 4 | 0.632 |
| Biological | 97 (80.8%) | 23 (19.2%) | 120 | |
| Device | 16 (66.7%) | 8 (33.3%) | 24 | |
| Dietary supplement | 7 (70.0%) | 3 (30.0%) | 10 | |
| Drug | 509 (80.7%) | 122 (19.3%) | 631 | |
| Genetic | 1 (50.0%) | 1 (50.0%) | 2 | |
| Procedure | 24 (80.0%) | 6 (20.0%) | 30 | |
| Radiation | 40 (83.3%) | 8 (16.7%) | 48 | |
| Other | 13 (76.5%) | 4 (23.5%) | 17 | |
| Gender | ||||
| Nonselective | 710 (80.3%) | 174 (19.7%) | 884 | 0.282 |
| Selective | 1 (50.0%) | 1 (50.0%) | 2 | |
| Phase | ||||
| 1 | 251 (80.4%) | 61 (19.6%) | 312 | 0.818 |
| 2 | 375 (80.6%) | 90 (19.4%) | 465 | |
| 3 | 40 (80.0%) | 10 (20.0%) | 50 | |
| 4 | 1 (50.0%) | 1 (50.0%) | 2 | |
| N/A | 44 (77.2%) | 13 (22.8%) | 57 | |
| Funding source | ||||
| Industry only | 151 (80.3%) | 37 (19.7%) | 188 | 0.266 |
| NIH only | 84 (84.0%) | 16 (16.0%) | 100 | |
| Other only | 178 (76.1%) | 56 (23.9%) | 234 | |
| Multi | 298 (81.9%) | 66 (18.1%) | 364 | |
| Randomization | ||||
| Randomized | 123 (79.4%) | 32 (20.6%) | 155 | < 0.0001 |
| Non-randomized | 171 (81.8%) | 38 (18.2%) | 209 | |
| Not applicable | 311 (75.7%) | 100 (24.3%) | 411 | |
| Not reported | 106 (95.5%) | 5 (4.5%) | 111 | |
| Intervention model | ||||
| Crossover | 5 (83.3%) | 1 (16.7%) | 6 | 0.0001 |
| Factorial | 1 (100%) | 0 (0.0%) | 1 | |
| Single-group | 416 (77.5%) | 121 (22.5%) | 537 | |
| Sequential | 16 (84.2%) | 3 (15.8%) | 19 | |
| Parallel | 154 (77.0%) | 46 (23.0%) | 200 | |
| Not reported | 119 (96.7%) | 4 (3.3%) | 123 | |
| Blinding | ||||
| Blinded | 36 (81.8%) | 8 (18.2%) | 44 | < 0.0001 |
| Unblinded | 578 (77.8%) | 165 (22.2%) | 743 | |
| N/A | 97 (98.0%) | 2 (2.0%) | 99 | |
| Primary purpose | ||||
| Basic science | 6 (66.7%) | 3 (33.3%) | 9 | 0.033 |
| Device feasibility | 1 (100%) | 0 (0%) | 1 | |
| Diagnostic | 24 (60.0%) | 16 (40.0%) | 40 | |
| Health services research | 3 (100%) | 0 (0%) | 3 | |
| Screening | 1 (100%) | 0 (0%) | 1 | |
| Supportive care | 14 (73.7%) | 5 (26.3%) | 19 | |
| Prevention | 0 (0%) | 1 (100%) | 1 | |
| Treatment | 651 (81.6%) | 147 (18.4%) | 798 | |
| Other | 8 (80.0%) | 2 (20.0%) | 10 | |
| Not reported | 3 (75.0%) | 1 (25.0%) | 4 | |
| Number of study centers | ||||
| Single center | 337 (76.2%) | 105 (23.6%) | 442 | 0.011 |
| Multicenter | 343 (84.5%) | 63 (15.5%) | 406 | |
| Not reported | 31 (81.6%) | 7 (18.4%) | 38 | |
| Age | ||||
| Child | 2 (66.7%) | 1 (33.3%) | 3 | 0.748 |
| Child, adult | 51 (76.1%) | 16 (23.9%) | 67 | |
| Child, adult | 35 (85.4%) | 6 (14.6%) | 41 | |
| Older adult | ||||
| Adult | 1 (100%) | 0 (0%) | 1 | |
| Adult, older adult | 615 (80.5%) | 149 (19.5%) | 764 | |
| Older adult | 7 (70.0%) | 3 (30.0%) | 10 | |
Significant values are identified in bold